ReviewChinese clinical oncology2015

The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer.

Vera Jean Suman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.